Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -3.07
- Piotroski Score 3.00
- Grade Buy
- Symbol (SELB)
- Company Selecta Biosciences, Inc.
- Price $0.88
- Changes Percentage (-8%)
- Change -$0.08
- Day Low $0.81
- Day High $0.94
- Year High $1.99
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in preclinical stage to improve the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. In addition, the company is developing gene therapies comprising SEL-313, a product candidate in preclinical stage to treat ornithine transcarbamylase deficiency; SEL-399, a product candidate to evaluate the appropriate dose of ImmTOR in humans to reduce the formation of antibodies to AAV capsids; and products for the treatment of pompe disease, duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorder, and other autoimmune diseases. Further, it develops tolerogenic therapies to treat primary biliary cholangitis and other autoimmune diseases. The company has license and collaboration agreements with Takeda Pharmaceuticals USA, Inc.; Swedish Orphan Biovitrum; Sarepta Therapeutics, Inc.; Asklepios Biopharmaceutical, Inc.; Massachusetts Institute of Technology; Shenyang Sunshine Pharmaceutical Co., Ltd.; Ginkgo Bioworks Holdings, Inc.; and IGAN Biosciences, Inc. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/12/2023
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.29
- Trailing P/E Ratio -3.0386206896552
- Forward P/E Ratio -3.0386206896552
- P/E Growth -3.0386206896552
- Net Income $-219,710,000
Income Statement
Quarterly
Annual
Latest News of SELB
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Elisabeth Hasselbeck says 'The View' will 'pump the girl candidate no matter what,' gender 'suddenly matters'
Former "Fox & Friends" co-host Elisabeth Hasselbeck criticized "The View" and media manipulation in the 2024 election, accusing Democrats of suddenly emphasizing gender. She believes the press is dive...
By Fox News | 3 months ago -
Trump ally Allen Weisselberg released from jail
Allen Weisselberg, former CFO of the Trump Organization, was released early from Rikers Island after being convicted of lying during a fraud trial. He served time for perjury and tax fraud, with his a...
By CNBC | 3 months ago -
Trump ex-deputy Weisselberg sentenced to five months for perjury
By Luc CohenNEW YORK (Reuters) -Former Trump Organization Chief Financial Officer Allen Weisselberg was sentenced on Wednesday to five months in jail after pleading guilty last month to perjury charge...
By Reuters | 7 months ago
